As Congress debates its next major healthcare package, one reform stands out for its ability to lower costs, strengthen competition, and protect patient choice: Site Neutrality. Today, federal policy pays hospital-owned facilities far more than independent physicians for the exact same service—a distortion that fuels consolidation, drives up prices, and Read more…
This holiday season, more than 11 million Americans will sit at the table with a loved one living with Alzheimer’s or another form of dementia. As Charles Sauer writes in BizPac Review, these moments are more than emotional — “they are a policy failure playing out in millions of American Read more…
A new analysis presented at CTAD 2025 by researchers at the USC Schaeffer Center offers one of the clearest pictures yet of how early intervention could transform the fight against Alzheimer’s disease. The findings show that anti-amyloid therapies, when started sooner, can meaningfully extend independence, reduce caregiver burden, and even Read more…
A common refrain from Trump supporters is that everything he is doing is “common sense.” And at some level, they’re right. Taking aggressive measures to lower crime, strengthen the economy, and fix broken markets like pharmaceuticals sounds like exactly what a president should do. But as Charles Sauer writes in Read more…
Populism has always had political appeal—and as recent elections show, it can win. But as Market Institute President Charles Sauer argues in RealClearHealth, some forms of populism trade long-term prosperity for short-term applause. “Populism makes sense as a political strategy – as we can see from Momdani’s win in NY, Read more…
More than 7 million Americans are currently living with Alzheimer’s — a number on track to double by 2050. Families across the country are already grappling with the emotional strain and the soaring financial cost of caring for loved ones. As Charles Sauer highlights in Politibrawl, this crisis is not Read more…
One reason libertarians don’t trust the government is because so many well-intentioned programs end up either making things worse for the supposed beneficiaries, enriching powerful interests — or both. Norm Singleton highlights one such example: the federal Section 340B prescription drug program, which has quietly ballooned into a multi-billion-dollar market Read more…
Following the end of the government shutdown, Congress and the White House are preparing to negotiate a Fiscal Year 2026 spending bill. One of the key issues on the table will be whether to extend the so-called “temporary” Obamacare subsidies first passed as part of the 2021 Covid relief bill. Read more…
Democrats think they can win the looming government shutdown debate by focusing on healthcare — one of the few issues where polling consistently shows they have an advantage.
Medicare is running out of money, with insolvency projected by 2033. While lawmakers, providers, and regulators acknowledge the looming crisis, little is being done to address one of the biggest drivers of waste: Medicare Advantage. As Charles Sauer writes in InsideSources: “One of the most significant issues is Medicare Advantage, Read more…